---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-072608"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T00:59:47.396775+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma regains Nasdaq compliance after equity-boosting transactions totaling ~$10.65M

## Summary
- Company completed four transactions increasing stockholders' equity by ~$10.65M to meet Nasdaq listing requirement.
- Issued 300K shares and 200K pre-funded warrants on July 31, raising $1.75M in equity.
- Note conversion of $500K on Aug 1 added $0.5M; $308K note repayment via 176,678 shares added $1M more.
- Agreed to acquire 20% of property from Zhonghui for 370K shares, expected to add $7.4M (closing pending).
- Nasdaq will continue to monitor compliance; delisting risk remains if not maintained at next periodic report.

## SEC filing metadata
- accession: 0001213900-23-072608
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023072608/0001213900-23-072608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023072608/ea184468-8k_abvc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-072608
- JSON: https://secwatch.observer/filing/0001213900-23-072608.json
- Plain text: https://secwatch.observer/filing/0001213900-23-072608.txt

## Key facts
- Listing & Compliance Notices
  ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding stockholders equity.
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: stockholders equity
  source text: July 31, 2023, the Company issued 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share, in a registered direct offering. Pursuant to this transaction, the stockholders’ equity was increased by $1.75M. We also previously disclosed that on August 1, 2023, the holder of $500,000 of Notes (as hereinafter defined) converted such notes at $3.50 per share and received 142,857 shares of Common Stock. As a result of this conversion, the stockholders’ equity was increased by $0.5M. Additionally, as previ
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023072608/0001213900-23-072608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.